The partnership will develop non-invasive, individualised and peripheral nerve stimulation therapies
Bioelectronic medicine company Cala Health has entered into a partnership with the University of California, San Francisco (UCSF) to develop next-generation and smart neuromodulation therapies.
The partnership will focus on the development of non-invasive, individualised and peripheral nerve stimulation therapies, which leverage Cala Health’s neuromodulation and data science platform technology.
Cala Health will work with UCSF Weill Institute of Neuroscience associate professor and neural engineering expert Dr Karunesh Ganguly to provide non-invasive treatments for serious neurological conditions.
In a statement, Ganguly said: “In my clinical work, I see the profound impacts of motor impairments from a wide range of neurological conditions such as brain injury and Parkinson’s disease, and we are committed to advancing new treatments to enhance motor function.”
The technologies licenced from UCSF will allow the firm to expand its pipeline of therapies in neurology, helping to build on the recent launch of Cala Trio Transcutaneous Afferent Patterned Stimulation (TAPS) therapy for hand tremors from a movement disorder known as essential tremor.
Cala Trio is claimed to be the only non-invasive and wrist-worn prescription therapy presently available for essential tremor.
Also, the partnership will further expand Cala Health’s mechanistic research on novel individualised therapies, as well as the incorporation of a data science platform to boost a software-enabled future to provide tailored treatment insights to the right patients at the right time.
Cala Health founder and chief scientific officer Dr Kate Rosenbluth said: “Dr. Ganguly’s pioneering research on the precise targeting of electrical stimulation to modulate neural networks provides an exciting path to personalise therapy to each patient.
“This partnership takes Cala Health one step closer to reaching our goal to give the millions of patients suffering from debilitating neurological disorders access to non-invasive, efficacious therapies that improve their quality of life.”